Maplight Therapeutics (NASDAQ:MPLT) Shares Up 6.8% – Here’s Why

Posted by Stacy Sanders on Dec 10th, 2025

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report)’s share price was up 6.8% during trading on Wednesday . The company traded as high as $20.45 and last traded at $20.14. Approximately 102,344 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 281,291 shares. The stock had previously closed at $18.85.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on MPLT. Zacks Research raised Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. Leerink Partners started coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price objective for the company. Morgan Stanley began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set an “overweight” rating and a $34.00 target price on the stock. Jefferies Financial Group started coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $32.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $28.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $31.00.

View Our Latest Analysis on Maplight Therapeutics

Maplight Therapeutics Stock Performance

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last posted its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.86) by ($35.32).

Maplight Therapeutics Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.